Am J Transplant, Volume 19, Suppl 3 Archives - Page 129 of 214 - ATC Abstracts

2019 American Transplant Congress
Management of Dyslipidemia after Liver Transplantation
S. S. Patel¹, V. A. Rodriguez², M. B. Siddiqui¹, M. Faridnia³, F. Lin⁴, J. Laurenzano⁴, J. Clinton⁴, A. Chandrakumaran³, T. Reichman⁵, C. Bhati⁵, M. S. Siddiqui¹
¹Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, ²Department of Bio-statistics, Virginia Commonwealth University, Richmond, VA, ³Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Department of Transplant Surgery, Virginia Commonwealth University, Richmond, VA
*Purpose: Cardiovascular disease (CVD) remains a major cause of long-term mortality in liver transplant recipients (LTR). Adequate control of CVD risk factors like hypertension, diabetes,…
2019 American Transplant Congress
Anticoagulation in Post-Liver Transplant Recipients with Portal Vein Thrombosis
L. Schumacher¹, L. Lindberg¹, D. Alonso², R. Gilroy³, J. Krong⁴, L. Dong⁴, S. LeCorchick¹
¹Department of Pharmacy, Intermountain Medical Center, Murray, UT, ²Transplant Surgery, Intermountain Medical Center, Murray, UT, ³Transplant Hepatology, Intermountain Medical Center, Murray, UT, ⁴Department of Transplant, Intermountain Medical Center, Murray, UT
*Purpose: The purpose of this study is to compare safety and efficacy outcomes in liver transplant recipients with portal vein thrombosis (PVT) at the time…
2019 American Transplant Congress
Higher Incidence of Coagulation Complications in Live Liver Donation
B. Movahedi, p. Mahboub, N. Kim, P. Martins, A. Bozorgzadeh
Surgery, UMass Memorial Medical Center, Worcester, MA
*Purpose: Live donor liver and kidney donations are very effective procedures to increase the available organ pool and shorten waiting list for the patients listed…
2019 American Transplant Congress
Patients with Immunological Diseases or on Peritoneal Dialysis Are Prone to False Positive Flow Cytometry Cross Match
Q. Xu¹, A. House², S. Leckie¹, L. Gunaratnam², P. Luke³, A. Jevnikar²
¹Pathology and Lab Medicine, London Health Science Center, London, ON, Canada, ²Medicine, Western University, London, ON, Canada, ³Surgery, Western University, London, ON, Canada
*Purpose: Despite implementation of virtual cross matches, flow cytometry cross matches (FCXM) are still used by many transplant centers to determine immunological risk prior to…
2019 American Transplant Congress
Targeting Pyroptosis in Brain-Dead Donors Improves Renal Function after Transplantation in Rat
H. Yang¹, Y. Shi², X. Li¹, L. Luo¹, C. Long¹, Y. Xiong³, M. Chen⁴, J. Gao⁴, H. Li⁵, Z. Wang⁵
¹Department of Organ Transplantation, People's Hospital of Jiangxi Province, Nanchang, China, ²Department of Pathology, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ³Department of Neurology, People's Hospital of Jiangxi Province, Nanchang, China, ⁴Department of Vascular Surgery, People's Hospital of Jiangxi Province, Nanchang, China, ⁵Department of Urologic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
*Purpose: Pyroptosis is a form of programmed cell death include necrosis, nuclear condensation, and release of proinflammatory after caspase-1 activation. It is unknown whether pyroptosis…
2019 American Transplant Congress
Peripheral Blood Chemokine Levels in Kidney Allograft Rejection
E. Van Loon, D. Schols, S. Claes, M. Naesens
University Hospitals Leuven, Leuven, Belgium
*Purpose: Cytokines and chemokines play a critical role in acute rejection after kidney transplantation and may be of importance in the quest for better diagnostic…
2019 American Transplant Congress
Association of Histological Findings in Renal Graft Biopsy with Non-Adherence to Immunosuppressive Treatment
B. D. Cardoso¹, J. Montagner², K. Pegas³, R. Kist⁴, J. Neumann⁵, H. S. Pinheiro⁶, V. D. Garcia⁴, E. Keitel¹
¹Department of Nephrology and Kidney Transplantation/ Post Graduation Program in Pathology, Irmandade Santa Casa de Misericórdia/ Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil, ²Transplant Immunology Laboratory,, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, ³Department of Pathology, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, ⁴Department of Nephrology and Kidney Transplantation, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, ⁵Transplant Immunology Laboratory, Irmandade Santa Casa de Misericórdia, Porto Alegre, Brazil, ⁶Renal Transplant Unit, NIEPEN/NIDEAL (UFJF), Porto Alegre, Brazil
*Purpose: Non-adherence to immunosuppressive treatment after renal transplantation is a frequent issue, but the magnitude of its impact has been debated. It is unknown whether…
2019 American Transplant Congress
Calcineurin Inhibitors and Long-Term Outcomes of Kidney Transplantation from Thai Transplant Registry
S. Udomkarnjananun, N. Townamchai, Y. Avihingsanon, K. Praditpornsilpa
Chulalongkorn University, Bangkok, Thailand
*Purpose: Calcineurin inhibitors (CNIs) have became the primary immunosuppressive medications (IS) for kidney transplantation (KT) in the current era. However, the long-term outcomes of KT…
2019 American Transplant Congress
Impact of Delayed Graft Function on Allograft Survival in DCD versus DBD Kidneys
T. Ishaque, A. B. Massie, J. Ruck, C. Holscher, J. G. Wang, D. L. Segev
Surgery, Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: Several single-center studies have suggested no link between delayed graft function (DGF) and graft survival in recipients of donation after cardiac death (DCD) kidneys,…
2019 American Transplant Congress
Assessment of Health-Related Quality of Life and Graft Failure among Kidney Transplant Patients in the Benefit and Benefit-EXT Trials
I. Purnajo¹, J. L. Beaumont¹, M. Polinsky², E. Alemao², M. J. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Bristol Myers Squibb, Princeton, NJ
*Purpose: To achieve patient focused drug development in renal transplant, we need to better understand how the patient’s perspective of health-related quality of life (HRQoL)…